ADIOS – adaptive ocrelizumab dosing study

21 September, 2020 | Posted in:

Dear MS Academy Member, We are exploring a funding application to perform an Adaptive Ocrelizumab Dosing Study or ADIOS trial. The idea is to try and adjust the dosing regimen of ocrelizumab to derisk some of the emerging adverse events associated with long-term B cell depletion. Would you be interested in participating? If yes, do you mind completing the […]

Continue Reading »

International Virtual MasterClass – the first of its kind!

17 September, 2020 | Posted in:

Our first ever International Virtual MasterClass ran last month over a period of two weeks, attended by 53 healthcare professionals from around the globe.  Co-created by Roche Egypt, the MasterClass was specifically focussed on multiple sclerosis (MS), and provided a virtual learning experience for delegates across 10 countries (table 1) where specialists in the condition […]

Continue Reading »

Essential neurorehabilitation in the aftermath of COVID-19

6 July, 2020 | Posted in: ,

The impact of coronavirus on our health service has been highly documented, but with the first wave passed, the burden has not lifted, but altered, in the form of rehabilitation. Earlier this week, we highlighted an article in Reuters which has since been echoed in multiple publications – the long-term implications of COVID-19 on a […]

Continue Reading »

World MS Day 2020

30 May, 2020 | Posted in:

World MS is officially marked on 30th May. It brings the global MS community together to share stories, raise awareness and campaign with everyone affected by multiple sclerosis (MS). World MS Day activities take place throughout the month of May and in early June. The campaign offers flexibility for individuals and organisations to achieve a […]

Continue Reading »

Fampyra approved in Scotland

17 April, 2020 | Posted in:

The Scottish Medicines Consortium (SMC) have approved ‘Fampyra’ for use by people living with multiple sclerosis (MS) in Scotland. Around 2 in 3 people with MS will develop walking difficulties and the drug, fampridine, improves walking ability in those responsive to it; around 1 in 3 people who try it (Biogen). Developed by Biogen Idec, […]

Continue Reading »

Paper published on disease-modifying therapies for MS and COVID-19

17 April, 2020 | Posted in: , ,

Professor Gavin Giovannoni has published a commentary paper on ‘The COVID-19 pandemic and the use of MS disease-modifying therapies’ in Elsevier.  During the coronavirus pandemic, one of the biggest areas of discussion and concern amongst the multiple sclerosis (MS) community has been around disease-modifying therapies. From what to begin and how, to safe monitoring, to […]

Continue Reading »

MS Academy in Neurodigest

17 April, 2020 | Posted in: ,

Neurodigest have just published a piece on how unique education creates clinical leaders and transforms services.  Part of Neurology Academy, whose vision is to deliver uniquely practical education to produce specialist clinical leaders and transform local healthcare, MS Academy’s variety of bespoke courses follows the hugely successful model established 18 years ago for Parkinson’s. Fully […]

Continue Reading »

New MS prevalence data and smoking statistics

17 March, 2020 | Posted in:

A new briefing from Public Health England has issued new prevalence data on MS and links with smoking. Seeking insight into the characteristics of people with MS, the briefing was developed in collaboration with the MS Society and using the THIN dataset.   The evidence, which was gathered over an eight year period from financial […]

Continue Reading »